Amoxicillin & Methotrexate Interaction

Amoxicillin can significantly increase methotrexate plasma concentrations by reducing its renal clearance, potentially leading to severe and life-threatening methotrexate toxicity ^[1]. Methotrexate is a narrow-therapeutic-index drug used for conditions including rheumatoid arthritis, psoriasis, and various cancers, where even modest increases in drug levels can cause serious adverse effects ^[2]. The interaction between penicillin-class antibiotics and methotrexate has been documented in case reports describing pancytopenia, mucositis, renal failure, and death following concurrent administration ^[1][3].

This interaction is particularly dangerous because patients on methotrexate frequently develop infections that may require antibiotic therapy, and amoxicillin is one of the most commonly prescribed antibiotics ^[2]. The risk is dose-dependent and is greatest with high-dose methotrexate regimens used in oncology, but clinically significant interactions have also been reported with the lower doses used in rheumatology and dermatology ^[3].

Methotrexate is eliminated primarily through renal excretion, involving both glomerular filtration and active tubular secretion via organic anion transporters (OATs), particularly OAT1 and OAT3 in the proximal tubule ^[1]. Amoxicillin is also secreted by renal tubular OATs and competes with methotrexate for these transport proteins, reducing methotrexate's renal clearance ^[2]. This competitive inhibition at the tubular level results in elevated methotrexate plasma concentrations and prolonged exposure ^[1]. Additionally, amoxicillin can reduce renal blood flow via its effects on prostaglandin synthesis (though this mechanism is more prominent with NSAIDs) and may alter the intestinal flora involved in methotrexate enterohepatic recirculation ^[3]. The magnitude of the interaction depends on renal function, methotrexate dose, hydration status, and the duration of concurrent antibiotic therapy ^[2].

Case reports have documented severe methotrexate toxicity — including fatal pancytopenia, severe mucositis, hepatotoxicity, and acute kidney injury — following concurrent amoxicillin use ^[1]. The risk is elevated in patients with impaired renal function, dehydration, hypoalbuminemia, or advanced age ^[2]. Even at the lower doses of methotrexate used for rheumatoid arthritis (7.5-25 mg weekly), delayed clearance can result in prolonged exposure to cytotoxic drug levels, with bone marrow suppression manifesting 7-14 days after the offending methotrexate dose ^[3]. In high-dose methotrexate protocols used in oncology (≥500 mg/m²), the interaction can be acutely dangerous, with methotrexate levels failing to clear within expected timeframes ^[1]. The insidious nature of the interaction — toxicity appearing days after the interacting doses — makes it particularly hazardous, as the causal link may not be immediately recognized ^[3].

Avoid amoxicillin in patients on methotrexate when alternative antibiotics are available ^[1]. If concurrent use is unavoidable, reduce the methotrexate dose or temporarily hold methotrexate during the antibiotic course, with guidance from the prescribing rheumatologist or oncologist ^[2]. Ensure the patient is well-hydrated to maximize renal clearance of methotrexate ^[1]. In patients on high-dose methotrexate, amoxicillin should be avoided entirely — use antibiotics that do not interfere with renal tubular transport, such as fluoroquinolones (with caution) or azithromycin ^[3]. If the patient develops signs of methotrexate toxicity during concurrent amoxicillin use, discontinue both drugs immediately, administer leucovorin rescue (folinic acid), ensure aggressive IV hydration, and consult hematology/oncology ^[1]. Urine alkalinization (pH > 7.0) can enhance methotrexate solubility and renal elimination ^[2].

Obtain a complete blood count (CBC) with differential before starting amoxicillin in patients on methotrexate, and repeat CBC at 7 and 14 days after completing the antibiotic course to detect delayed bone marrow suppression ^[1]. Monitor serum creatinine and BUN to assess renal function ^[2]. In patients on high-dose methotrexate, measure methotrexate levels at standard intervals — delayed clearance (levels >0.1 µmol/L at 48 hours) requires continued leucovorin rescue ^[1]. Watch for clinical signs of toxicity: oral ulcers or mucositis, unusual bleeding or bruising, fever or signs of infection (indicating neutropenia), nausea, vomiting, diarrhea, jaundice, and dark urine ^[3]. Liver function tests (AST, ALT, bilirubin) should be monitored if concurrent use extends beyond 7 days ^[2].

For bacterial infections in methotrexate patients, azithromycin has minimal effect on renal tubular transport and is generally considered safer ^[3]. Cephalosporins (cephalexin, cefdinir) have a lower risk of interfering with methotrexate clearance compared to penicillins, though they should still be used with monitoring ^[2]. For urinary tract infections, nitrofurantoin does not interfere with methotrexate renal clearance ^[1]. For skin and soft tissue infections, clindamycin is an alternative without known methotrexate interaction ^[3]. When amoxicillin is being used for Helicobacter pylori eradication, clarithromycin-based regimens may be substituted (though clarithromycin has its own drug interactions to consider) ^[2]. Always consult the prescribing rheumatologist or oncologist before selecting an antibiotic in patients on methotrexate ^[1].